Please select the option that best describes you:
How should young patients with rhabdomyosarcoma be managed in the absence of a clinical trial?
-Are there settings where group II disease does not need RT?
-Are there additional genetic alterations in fusion negative RMS patients that can be used to further risk-adapt therapy?
-Should we uniformly apply RT guidelines regardless of age (what about infants)?
-Should RT doses change in light of the higher failure w/low dose cyclophosphamide or should we use higher doses of cyclo?
Answer from: Radiation Oncologist at Academic Institution
The guiding principles of disease control while maintaining form, function, and quality of life drive the decision-making and management for patients with rhabdomyosarcoma.Regarding patients with paratesticular primary, inguinal orchiectomy with no scrotal invasion but tumor on the surface of the re...
Sign in or Register to read more